Скачать или смотреть The 'New' Obagi Strategy and the Economics of Clinical Wellness

In this episode, host Don Adeesha sits down with Drew Fine, U.S. general manager for the professional channel at Obagi Medical, to explore the shift from traditional lab studies to real-world clinical data. Drew explains why standard clinical trials are no longer enough and introduces the Aloha program, an initiative designed to gather practice-based evidence and give clinic owners a direct seat at the R&D table.


Drew breaks down the strategy behind launching a new premium HA filler in a saturated market, emphasizing the power of integrating skincare with injectables to improve patient outcomes and increase average ticket sizes. He challenges the traditional, transactional vendor relationship, advocating for transparent partnerships that eliminate complicated contracts, volume-based inventory handcuffs, and fluctuating costs.


Finally, Drew details how to operationalize clinical wellness as a powerful retention engine rather than relying on short-term discount wars. Drawing from his leadership experience at Allergan, Galderma, and Obagi, he reveals the single non-negotiable operational trait shared by the top one percent of scaling practices: an exceptional workplace culture where teams do excellent work, have fun, and continuously learn.